NCT07175493 - A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions

Autoimmune CytopeniaImmune Thrombocytopenia (ITP)Autoimmune Hemolytic AnemiaEvans Syndrome

Interventions

BIOLOGICAL

CM336 Injection

subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol

Trial Locations (1)

Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin